Research programme: second generation toll-like receptor 2 antagonists - Neuropore Therapies
Latest Information Update: 04 Feb 2021
At a glance
- Originator Neuropore Therapies
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Toll-like receptor 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Neurological disorders
Most Recent Events
- 08 Sep 2020 Early research in Neurological disorders in USA (unspecified route) before September 2020 (Neuropore Therapies pipeline, September 2020)